Article info

Download PDFPDF
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

Authors

  1. Correspondence to Dr Joyce Liu, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; joyce_liu{at}dfci.harvard.edu
View Full Text

Citation

Liu J, Oza AM, Colombo N, et al
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

Publication history

  • Accepted October 13, 2021
  • First published October 29, 2021.
Online issue publication 
January 03, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.